Slides
Page 1
& Probiotics Y bioties & Probiot os & Probiotics vive Heal ganic 12 FLOZC Vi suja IMMMUNITY GINGER PINEAPPLI MMUNITY BOOST sul vive vive GEST organic organic IMMUNITY BOOST ORIGINAL NGER & TURMERIC SUPPLEMENT FL IMMUNITY BOOST VALUE PACK SHOTS SUPPLY vive ORIGINAL organic IMMUNITY BOOST MIX PACK 22K YOU MAY BOTTLES NET OFLQZ ( 236 mL ) Second Quarter 2026 Earnings Results Prebiotics & Probiale Problatios & Cola Health Grape Healt Soda Soda 12 FL OZ 12 FLO suja GUT HEAL Berry Lemon BOOSTED BY Probiotics Prebiotic Fibe Lemon Tart Cherry ENT ENHANCED FRUIT JU suja IMMUNITY ELDERBERRY APPLE Prob suja LIFE
Page 2
Page | 2 Disclaimer Forward - Looking Statements This presentation and related conference call contain forward - looking statements that are subject to risks and uncertainties. Al l statements other than statements of historical fact included in this presentation and related conference call are forward - look ing statements. Forward - looking statements give our current expectations and projections relating to our financial condition, results of operati ons, plans, objectives, future performance and business. You can identify forward - looking statements by the fact that they do no t relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “pl an, ” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely” and other words and terms of similar meaning in connecti on with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to expected consumer spending, macro - economic and competitive pressures, velocity rates, marketing and distributio n initiatives and their expected benefits, growth rates and future financial results and outlook, the potential refinancing of ind ebtedness, long - term targets, estimated costs, expenditures, cash flows, our plans and objectives for future operations, growth or initiatives, strategies or the expected outcome or impact of pending or threatened litigation are forward - looking statements. All forward - loo king statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we exp ected, including: an overall decline in the health of the economy and other factors impacting consumer spending; a reduction in dema nd for and sales of our cold - pressed juices, wellness shots and functional sodas or a decrease in consumer demand for such products generally; strong competition in the food and beverage retail industry; the success of our marketing strategies and channels at maintain ing consumer awareness of our brands, building brand loyalty and generating interest in our products from existing and new consum er s; a reduction or limited availability of organic fruits, vegetables and other raw materials and ingredients for our juice product s, or an increase in the price of such materials and ingredients; real or perceived quality or food safety issues with our produ cts , which may diminish our brands and reputation; our ability to refinance our indebtedness; our reliance on distributor and retail customers for a sig nificant portion of our sales, and our ability to maintain or further develop our sales channels; our reliance on our local a nd regional farming partners and other third - party partners and those third parties’ ability to fulfill their obligations; our reliance on our limit ed suppliers for materials used to package our products, the costs of which have in the past been, and may continue to be, vo lat ile and subject to price increases; failure by our transportation providers to deliver our products on time, or at all, and problems with our lo gis tics network and arrangements; our ability to manage our future growth effectively; our ability to successfully forecast and man age our inventory at appropriate levels for our demand; the seasonal nature of our business, which may cause our quarterly results to fluctuate an d may not be indicative of full - year performance; any damage or disruption at our production facilities in Oceanside, California , where our products are primarily manufactured; our ability to quickly respond to new trends by introducing new products or successfully im proving existing products; our ability to develop and maintain our brands and company image ; our success with making acquisi tio ns and integrating newly acquired products or businesses; and the other factors set forth in our filings with the U.S. Securities an d E xchange Commission (the “SEC”). All written and oral forward - looking statements attributable to us, or people acting on our behalf, are expressly qualified in t heir entirety by these cautionary statements as well as other cautionary statements that are made from time to time in our ot her SEC filings and public communications. You should evaluate all forward - looking statements made in this presentation and related conference call in the context of these risks and uncertainties. The forward - looking statements included in this presentation and related confer ence call are made only as of the date hereof. We undertake no obligation to update or revise any forward - looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Non - GAAP Financial Measures We use certain non - GAAP key performance indicators to evaluate our business operations, including EBITDA, Adjusted EBITDA and Ad justed EBITDA Margin. The non - GAAP financial measures presented in this presentation and related conference call are supplementa l measures of our performance that we believe help investors understand our financial condition and operating results and asses s o ur future prospects. We believe that these non - GAAP financial measures provide investors with greater transparency to the inform ation used by management for its operational decision - making. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance. Management recognizes that these non - GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes, thereby affecting their comparabil it y from company to company. In order to compensate for these and the other limitations discussed below, management does not consider the se measures in isolation from or as alternatives to the comparable financial measures determined in accordance with GAAP. Ple ase review the definitions and reconciliations included in the Appendix.
Page 3
Colour 1 R # G # B # Colour 2 R # G # B # Colour 3 R # G # B # Colour 4 R # G # B # Colour 5 R # G # B # Colour 6 R # G # B # 3 APPROACHABLE & ACCESSIBLE REAL, FUNCTIONAL NUTRITION GREAT TASTE Our Purpose To Change What Beverages Bring to the Table
Page 4
Page | 4 We Are A Growing Platform In Natural Healthy Beverage Suja Life operates in some of the fastest-growing parts of beverage, in one of the best positions in the store, with a platform retailers trust and consumers choose. Page | 4 Source: NielsenIQ Scantrack Total US xAOC+Conv 13wk End 06/27/26
Page 5
Page | 5 The Suja Life Platform Category - Leading Brands Vertically - Integrated Manufacturing National Retail Leadership #1 In Cold-Pressed Juice Retail Sales (1) #1 Wellness Shot Brand in Retail Sales (1) 28% Brand Awareness, Year 1 (2) 33K+ Total Retail Stores Nationwide (1) 383K+ Points of Distribution (3) 30+ Relationships as Strategic Advisor or Category Captain 100% CPJ & Wellness Shots Produced In-House 270K Sq. Ft. Multi-Building Campus, Oceanside CA 8 days From Farm to Bottle Source: 1) NielsenIQScantrackTotal US xAOC+Conv 13wk End 06/27/26, 2) 2025 Company Survey, 2025 3) Company Estimates based on NielsenIQScantrackTotal US xAOC+Conv 13wk End 06/27/26
Page 6
Page | 6 Q2 2026 Highlights $83.9M Net Sales 46.7% Gross Profit Margin $14.6M Adjusted EBITDA(1) 17.5% Adj. EBITDA Margin(1) Segment Performance Suja Core Net Sales: $81.9M | +9.8% vs Q2 2025 Wellness shots saw double-digit growth in Q2; multi-pack formats signaled higher consumer adoption versus prior year. Q2 margin change versus PY primarily from absorption timing Emerging Brands (Slice) Net Sales: $3.0M | +61.2% vs Q2 2025 Continued distribution expansion and trial growth in second year on shelf combined with Dirty Soda innovation strength +11.6% vs. Prior Year (70bps) vs. Prior Year +50.0% vs. Prior Year +450bps vs. Prior Year (1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. See appendix for a definition and reconciliation to the most closely comparable GAAP measure.
Page 7
Page | 7 Suja Life’s categories are among the fastest growing in beverage… …and our brands are capturing share of Natural Healthy Beverage 6.9% 7.1% 9.1% 10.6% 2023 2024 2025 YTD $ % Chg vs YA Natural Healthy Beverage $ Shr 13% 13% 26% 7% 3% 1% 0% -1% 2% Cold-Pressed Juice and Wellness Shots Better-for-you Soda Coconut Water Energy Drinks Soft Drinks Sport Drinks Water RTD Coffee Total Beverage Source: NielsenIQ Scantrack Total US xAOC+Conv 13wk End 06/27/26 Category Tailwinds and Significant Share Position Suja Life for Continued Growth
Page 8
Page | 8 Household Penetration (%) 5 6 7 8 9 10 11 12 13 +350bps in 2 years Value Per Buyer ($) 22 23 24 25 26 27 28 29 30 31 +$4.43 spend per buyer Household penetration up 350bps to 11.1%, still significant whitespace ahead Spend per buyer up $4.43 to $29.78, loyalty deepening as portfolio expands Both metrics rising together = acquiring new consumers while retaining existing ones Consumer Adoption: Track Record of Growing Households & Deepening Spend Suja Life has expanded its consumer base and increased spend per buyer, a dual flywheel for durable revenue growth. 7.6% 11.1% $25.35 $29.78 Source: NielsenIQ Omnishopper Total US Total Outlet, 52 weeks ending 06/13/2026. NielsenIQ Omnishopper Penetration Enhancement (July 7) that strengthened panel quality, representativeness, and reliability by increasing period-to-period panelist continuity across the full Omni history. As part of this enhancement, historical penetration and buyer metrics were recalculated, which can result in shifts when comparing data pulls taken before and after the update.
Page 9
Page | 9 in Co ld Pres s ed Juic e Ret ail Sales (1)#1 in Welln es s Sh o t s Ret ail Sales (1)#1 34% Sh are o f Co ld Pres s ed Juic e (1) 44% Sh are o f Co ld Pres s ed Sh o ts (1) NPS 55 ( up fro m 39 in 3 mo n t hs ) (2) $219M 2 02 5 Net Sales $63M 2 02 5 Net Sales $10M 2 02 5 Net Sales 21%+ $V o l (1) 4%+ $V o l (1) +67% $V o l (1) Bran d Awaren es s fo r Slic e (2)28% Suja Life’s Brands Represent Multiple Levers of Growth Source: 1) NielsenIQ Scantrack Total US xAOC+Conv 13wk End 06/27/26, 2) Company Survey as of 9/25 Total US xAOC+Conv 13wk End 06/27/26 $ Share $ % Chg vs YA Syndicated Custom DB Syndicated Custom DB Suja Life Share of CPJ Juice & Shots 38.5% 37.3% 8% 11%
Page 10
Page | 10 Seasonality Q2 Note • Net sales are typically weighted heavier in Q1 and Q4 with cold flu season / New Year wellness cycle Key Growth Drivers Volume growth Broad-based across key products and retailers Distribution gains New product placements in existing new doors Promotional effectiveness Improved consumer takeaway at retail Mix shift Higher-margin wellness shots multi-pack formats Operating leverage OPEX leveraged 360bps YoY $ in millions Q2 2026 Q2 2025 Change Net Sales $83.9M $75.2M +11.6% Gross Profit $39.2M $35.6M +9.9% Gross Margin 46.7% 47.4% (70)bps Operating Expenses $34.6M $33.8M +2.6% Transaction Costs $25.1M - - OPEX of Net Sales 41.3% 44.9% +360bps Net Income (Loss) (1) ($27.8M) ($5.7M) IPO Impacted Adjusted EBITDA (2) $14.6M $9.8M +50.0% Adj. EBITDA Margin (2) 17.5% 13.0% +450bps Q2 2026 Financial Results (1) Includes $25.1M of one time IPO related transaction costs and $2.3M loss on debt extinguishment (2) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. See appendix for a definition and reconciliation to the most closely comparable GAAP measure.
Page 11
Page | 11 2026 Full Year Outlook Updates fiscal year 2026 outlook Guidance reflects management’s expectations as of August 4, 2026. See Forward Looking Statements disclosure. Suja Life does not undertake obligation to update guidance except as required by law. (1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. See appendix for a definition and reconciliation to the most closely comparable GAAP measure. Suja is unable to provide a reconciliation for forward-looking outlook of Adjusted EBITDA and Adjusted EBITDA margin to net income (loss) without unreasonable effort, because certain material reconciling items cannot be estimated due to factors outside of Suja’s control and could have a material impact on the reported results. Metric FY2025 Actual Prior FY2026 Guidance as of June 9, 2026 Updated FY2026 Guidance as of August 4, 2026 Net Sales $326.6M $367M – $371M (12.4% to 13.6% growth) $360M – $369M (10.2% to 13.0% growth) Adjusted EBITDA(1) $40.5M $70M – $72M (72.8% to 77.7% growth) $70M – $72M (72.8% to 77.7% growth) Adj. EBITDA Margin(1) 12.4% 19.1% – 19.4% 19.4% – 19.5%
Page 12
Page | 12 Why Suja Life – The Investment Thesis Category Leader in Fast - Growing Segments Proven Consumer Flywheel Clear Margin Expansion Path Durable Competitive Moat Multi - Brand Platform with Multiple Growth Levers Solid Second Quarter of 2026 #1 in cold-pressed juice (1) (34% share ( 1 )). #1 in wellness shots (1). Competing in some of the fastest growing categories and gaining share of Natural Healthy Beverage Household penetration up 350bps to 11.1% over two years ( 2 ). Value per buyer up $4.43 to $29.78 (2 ). Simultaneously acquiring new consumers while deepening customer lifetime value. 48.9% gross margin in H1 2026 (+100bps YoY). Long-term target of ~50% gross margin with Adj. EBITDA margins in the low-20s% range. SG&A leveraging as scale grows. Vertically integrated supply chain built over more than a decade. 99%+ fill rates. 270K sq. ft. campus. Coast-to-coast cold-chain. Positioned as the low-cost producer in a high-barrier category. Distribution Expansion. Consumer Adoption. Ritualization of the Consumer. Innovation. There are many avenues of growth in the Suja Life portfolio. +11.6% net sales growth. +50.0% Adj. EBITDA(3) growth. 2026 Net Sales guidance of $360-$369 million; Adjusted EBITDA guidance of $70-$72 million Source: 1) NielsenIQScantrackTotal US xAOC+Conv13wk End 06/27/26, 2) NielsenIQ Omnishopper Total US Total Outlet, 52 weeks ending 06/13/2026, 3) Adjusted EBITDA is a non-GAAP financial measure. See appendix for a definition and reconciliation to the most closely comparable GAAP measure.
Page 13
Colour 1 R # G # B # Colour 2 R # G # B # Colour 3 R # G # B # Colour 4 R # G # B # Colour 5 R # G # B # Colour 6 R # G # B # Appendix
Page 14
Page | 14 EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin We define EBITDA as net income (loss) as adjusted to exclude tax expense, net interest expense, and depreciation and amortization. We define Adjusted EBITDA as EBITDA further adjusted to exclude share-based compensation expense, IPO-related costs and adjustments, sponsor fees which will not recur subsequent to the IPO, and other non-recurring expenses. We define Adjusted EBITDA Margin as Adjusted EBITDA divided by net sales. We believe that EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin are important metrics for management and investors in evaluating our operating results, as they exclude the impact of items that we do not consider reflective of our core business operations. These measures also facilitate consistent comparison of our operating performance over time and relative to our peers. (1) Non-Recurring Costs - for the three and six months ended June 29, 2026 consists of one-time costs relating to corporate strategy, executive recruiting and consulting relating to the IPO. For the three and six months ended June 30, 2025, it consists of consulting fees related to one-time system improvements, transaction bonuses, and other one-time transition costs. (2) Sponsor Costs - Includes fees paid in cash to the Company’ s sponsor which will not recur subsequent to the IPO. (3) Transaction Costs - Consists of non-recurring costs directly attributable to the Company's IPO, including IPO-related professional fees and expenses, equity-based compensation costs incurred as a result of the acceleration and modification of equity awards in connection with the IPO, one-time IPO-related transaction bonuses, roadshow and investor relation expenses, travel and logistical expenses related to IPO launch activities including NASDAQ listing events. These items are non-recurring in nature and do not reflect the Company's ongoing operating performance. Three Months Ended Six Months Ended ($ in thousands) June 29, 2026 June 30, 2025 June 29, 2026 June 30, 2025 EBITDA and Adjusted EBITDA: Net income (loss) (27,798) (5,658) (20,064) (6,450) Provision for income taxes (472) 148 593 1,028 Interest expense 5,423 7,491 12,896 14,937 Depreciation and amortization 7,561 6,909 14,739 13,839 EBITDA (15,286) 8,890 8,164 23,354 Incentive unit compensation 1,114 116 1,254 227 Non-recurring costs (1) 167 360 848 491 Sponsor costs (2) 1,303 398 2,055 741 Transaction costs (3) 25,077 — 25,077 — Loss on debt extinguishment 2,273 — 2,273 — Adjusted EBITDA 14,648 9,764 39,671 24,813 Net income (loss) margin (33.2) % (7.5) % (10.5) % (4.0) % Adjusted EBITDA margin 17.5 % 13.0 % 20.8 % 15.3 % EBITDA margin (18.2) % 11.8 % 4.3 % 14.4 %